Salanersen for Spinal Muscular Atrophy

(SOLAR Trial)

This trial tests a drug called salanersen to assist individuals with Spinal Muscular Atrophy (SMA), a condition where muscles malfunction due to low levels of a protein essential for movement. The trial aims to determine if salanersen can enhance muscle function by increasing this crucial protein. Participants will either have never received SMA treatment or will have been treated with a specific drug called risdiplam and will discontinue it for the study. Ideal candidates for the trial are those with SMA who can sit independently for at least 10 seconds. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to a potentially groundbreaking treatment for SMA.

If you are currently taking risdiplam, you will need to stop it for the duration of the study. The last dose of risdiplam should be taken the day before starting salanersen. The protocol does not specify about other medications, so it's best to discuss with the study team.

Research has shown that salanersen has been tested for safety in other studies. One study found that children with spinal muscular atrophy (SMA) tolerated salanersen well over a year. The treatment appeared to slow the gradual loss of nerve function and improve movement abilities.

Another study evaluated salanersen's safety and reported no serious health problems linked to the treatment. This suggests the treatment is generally safe. However, like any treatment, side effects can occur, but they were not significant in these studies.

Researchers are excited about salanersen for spinal muscular atrophy (SMA) because it offers a new approach compared to existing treatments like nusinersen and risdiplam. Unlike these treatments, which are often administered more frequently, salanersen is given just once a year via an intrathecal lumbar puncture. This less frequent dosing could potentially enhance convenience and adherence for patients and caregivers. Additionally, salanersen may offer benefits to those who have already been treated with risdiplam, suggesting potential flexibility and broad application in managing SMA.

Research has shown that salanersen may help treat spinal muscular atrophy (SMA). Studies have found that salanersen can slow nerve damage and improve movement in people with SMA. Early data indicated that patients experienced better mobility and could perform daily activities more easily. These findings suggest that salanersen increases the production of a protein called SMN, which is crucial for maintaining healthy nerves and muscles. In this trial, participants in both the Treatment-Naïve Cohort and the Risdiplam-Treated Cohort will receive salanersen. The evidence supports salanersen's potential to improve muscle and nerve function in those with SMA.¹⁶⁷⁸⁹